Bayer announces successful first phase trial of cell therapy for Parkinson's disease
Two more phases of human trials to follow
German pharmaceutical company Bayer reported on Wednesday that the first trials showed that an experimental treatment for Parkinson's disease using stem cells is well tolerated in humans and that the transplanted cells survive in the brains of patients.
Source. Reuters writes about it.
The trial was conducted on 12 volunteers. The first phase lasted more than a year.
The drugmaker noted that the positive results of the first phase using a drug called bemdaneprocel, manufactured by Bayer's subsidiary BlueRock Therapeutics, allowed it to move to the second of three phases of human trials.
Background. Earlier, the US regulator refused to approve the first Alzheimer's drug in almost 20 years. Experts believe that this drug can do more harm than good.
If you have read this article to the end, we hope that means it was useful for you.
We work to ensure that our journalistic and analytical work is of high quality, and we strive to perform it as competently as possible. This also requires financial independence. Support us for only UAH 196 per month.
Become a Mind subscriber for just USD 5 per month and support the development of independent business journalism!
You can unsubscribe at any time in your LIQPAY account or by sending us an email: [email protected]
